Oral presentation selected: Phase 1 findings from the ongoing BHV1530-101 study will be featured in an oral presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026), a leading international forum for early-phase oncology drug development.
SK Biopharmaceuticals to provide upfront and milestone payments related to the Kv7 platform up to $795 million, along with tiered royalties to Biohaven ranging from the mid-teens to low twenties on U.S. net sales of opakalim. Opakalim, the lead candidate from Biohaven's Kv7 platform, is a
NEW HAVEN, Conn., Aug. 25, 2026 /PRNewswire/ -- Biohaven Ltd. and/or its wholly owned subsidiaries (" Biohaven ") (NYSE: BHVN) and Yale University ("Yale") today announced that the U.S. District Court for the District of Delaware has entered judgment in their favor in the trade secret
First extracellular protein degraders in the clinic demonstrate rapid and robust pharmacodynamic effects and compelling safety in nearly 200 individuals dosed, Phase 3 trial underway Positive clinical biomarker and patient data presented from Biohaven's extracellular degrader platform demonstrated
Infinitum founder and Groq board director brings frontier AI and technology-investing expertise to Biohaven as the company advances AI-enabled approaches to drug development NEW HAVEN, Conn., Aug. 6, 2026 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN), a global biopharmaceutical company, today
NEW HAVEN, Conn., July 27, 2026 /PRNewswire/ -- Biohaven Ltd. and/or its wholly owned subsidiaries (" Biohaven ") (NYSE: BHVN) and Yale University ("Yale") today announced that a federal jury in the U.S. District Court for the District of Delaware returned a verdict in their favor in the trade
Biohaven also announces new clinical supply agreement with Regeneron to evaluate BHV-1530 in combination with cemiplimab (Libtayo®) Early clinical activity observed: Phase 1 dose-escalation data show early tumor reductions in patients with Fibroblast Growth Factor Receptor (FGFR)3-altered and